Market Research Logo

Global Antibiotics Partnering Terms and Agreements 2010 to 2018

Global Antibiotics Partnering Terms and Agreements 2010 to 2018

The Global Antibiotics Partnering Terms and Agreements 2010 to 2018 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in antibiotics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Antibiotics partnering contract documents
Top antibiotics deals by value

The Global Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

Antibiotics
Aminoglycosides
Cephalosporin
Clindamycin
Macrolides
Penicillin
Quinolones
Sulfonamides
Tetracycline

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 200 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibiotics deals since 2010. Deals are listed by headline value, signed by big pharma, most active antibiotics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotics dealmaking with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010. The chapter is organized by specific antibiotics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Report scope

Global Antibiotics Partnering Terms and Agreements 2010 to 2018 is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

Global Antibiotics Partnering Terms and Agreements 2010 to 2018 includes:

Trends in antibiotics dealmaking in the biopharma industry since 2010
Analysis of antibiotics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life antibiotics deals
Access to over 200 antibiotics deal records and contract documents where available
The leading antibody deals by value since 2010
Most active antibiotics dealmakers since 2010
The leading antibiotics partnering resources

In Global Antibiotics Partnering Terms and Agreements 2010 to 2018, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


  • Executive Summary
  • Introduction
  • Trends in antibiotics dealmaking
    • Introduction
    • Antibiotics partnering over the years
    • Most active antibiotics dealmakers
    • Antibiotics partnering by deal type
    • Antibiotics partnering by therapy area
    • Antibiotics partnering by industry sector
    • Deal terms for antibiotics partnering
      • Antibiotics partnering headline values
        • Table Antibiotics deals with a headline value
      • Antibiotics deal upfront payments
        • Table Antibiotics deals with an upfront value
      • Antibiotics deal milestone payments
        • Table Antibiotics deals with a milestone value
      • Antibiotics royalty rates
        • Table Antibiotics deals with a royalty rate value
    • The anatomy of an antibiotics deal
      • RRD International & Dipexium Pharmaceuticals -Feb 03 2014
      • Hospira & Cempra Pharmaceutical- July 01 2013
      • Astellas & Optimer Pharmaceuticals- Feb 7 2011
  • Leading antibiotics deals
    • Introduction
    • Top antibiotics deals by value
      • Table Top antibiotics deals by value since 2010
  • Most active antibiotics dealmakers
    • Introduction
    • Most active antibiotics dealmakers
    • Most active antibiotics partnering company profiles
      • Biomedical Advanced Research and Development Authority
      • Optimer Pharmaceuticals
      • Cempra Pharmaceutical
      • GlaxoSmithKline
      • National Institute of Allergy and Infectious Diseases
      • AstraZeneca
      • Astellas Pharma
      • Basilea Pharmaceutica
      • Tetraphase Pharmaceuticals
      • Achaogen
      • CARB-X
      • Cubist Pharmaceuticals
      • Dipexium Pharmaceuticals
      • Oragenics
      • Salix Pharmaceuticals
      • Trius Therapeutics
      • Wellcome Trust
      • Alfa Wassermann
      • Biocon
      • CUBRC
      • Roche
      • Summit Therapeutics
      • Curetis
      • Department of Health and Human Services
      • Enanta Pharmaceuticals
  • Antibiotics contracts dealmaking directory
    • Introduction
    • Antibiotics contracts dealmaking directory
  • Antibiotics dealmaking by technology type
    • Antibiotics
    • Aminoglycosides
    • Cephalosporin
    • Clindamycin
    • Macrolides
    • Metronidazole
    • Penicillin
    • Quinolones
    • Tetracycline
  • Partnering resource center
    • Online partnering
      • Table Online partnering resources
    • Partnering events
      • Table Forthcoming partnering events
    • Further reading on dealmaking
  • Appendices
    • Antibiotics deals by company A-Z
      • A*STAR Agency for Science, Technology and Research
      • Abbott Laboratories
      • Accelr8
      • Acella Pharmaceuticals
      • Achaogen
      • Actavis (name changed to Allergan)
      • Advanced Life Sciences
      • Advanced Technology Company
      • Advance Trading
      • Affibody
      • Akorn
      • Albert Einstein College of Medicine
      • Alfa Wassermann
      • ALK-Abello
      • Allegis Holdings
      • Allergan
      • AllerQuest
      • Amerigen Pharmaceuticals
      • AmpliPhi Biosciences
      • AMR
      • Anacor Pharmaceuticals
      • Anatara Lifesciences
      • Angelini Pharma
      • ANI Pharmaceuticals
      • Antibiotic Research UK
      • Aptalis Pharma
      • Aqua Pharmaceuticals
      • Aradigm
      • ArGEN-X
      • ARigen
      • ARK Diagnostics
      • Aspen Holding
      • Astellas Pharma
      • AstraZeneca
      • Aurobindo Pharma
      • Aurospharma Company
      • Auspherix
      • AvidBiotics
      • Aytu BioScience
      • Basilea Pharmaceutica
      • Bayer
      • Biocon
      • BioConnections
      • Biomedical Advanced Research and Development Authority
      • BioMerieux
      • Biophore Pharmaceuticals
      • Boston University
      • Cadila Pharmaceuticals
      • Cantab Anti-infectives
      • Cantab Biopharmaceuticals
      • CARB-X
      • Cardinal Health
      • Cardiome Pharma
      • Cempra Pharmaceutical
      • Centre for Drug Research and Development (CDRD)
      • Cepheid
      • Checkpoint Therapeutics
      • Cidara Therapeutics
      • Citius Pharmaceuticals
      • Clinigen
      • Colorado State University
      • Cook Medical
      • Creative Antibiotics
      • CSPC Pharmaceutical Group
      • Cubist Pharmaceuticals
      • CUBRC
      • Cumberland Pharmaceuticals
      • Cumencor Pharmaceuticals
      • Curetis
      • CURx Pharmaceuticals
      • Cystic Fibrosis Foundation
      • Cystic Fibrosis Foundation Therapeutics
      • D&A Pharma
      • Dana-Farber Cancer Institute
      • Debiopharm
      • Defence Science and Technology Laboratory
      • Defense Threat Reduction Agency
      • Department of Defense
      • Department of Health and Human Services
      • De Duve Institute
      • Diod
      • Dipexium Pharmaceuticals
      • Discuva
      • DKSH
      • Dr. Reddy's Laboratories
      • DSM Sinochem Pharmaceuticals
      • Durata Therapeutics
      • Eagle Pharmaceuticals
      • Emergent BioSolutions
      • Enanta Pharmaceuticals
      • Entasis Therapeutics
      • Enterome Bioscience
      • Ercros
      • Euprotec
      • Eurofarma
      • Eurofins Scientific
      • European Commission
      • European Union
      • Everest Medicines
      • Evolva
      • Evotec
      • Fedora Pharmaceuticals
      • Ferrer International
      • Flamel Technologies
      • Flemish agency for Innovation by Science and Technology
      • Foamix
      • FOB Synthesis
      • Forest Healthcare
      • Forest Laboratories
      • Forge Therapeutics
      • Forsyth Institute
      • France's General Directorate for Armaments
      • FSC Laboratories
      • Fundacion Medina
      • Galapagos
      • Galderma
      • GC Pharma
      • Genentech
      • Genetics Laboratory
      • Genzyme
      • Geom Therapeutics
      • Gilead Sciences
      • GlaxoSmithKline
      • Global Antibiotic Research and Development Partnership
      • Grunenthal
      • Gyma Laboratories of America
      • Hainan Haiyao
      • Harvard Medical School
      • Harvard University
      • Helperby Therapeutics
      • Heraeus
      • Hi-Tech Pharmacal
      • Hikma Pharmaceuticals
      • Hospira
      • ID Genomics
      • Imaxio
      • Ingenza
      • Innovate UK
      • Innovative Medicines Initiative (IMI)
      • InSite Vision
      • Intrexon
      • Iroko Pharmaceuticals
      • Jade Therapeutics
      • Johnson & Johnson
      • Johns Hopkins University
      • Kala Pharmaceuticals
      • Laboratory Corporation of America
      • Lawrence Livermore National Laboratory
      • LegoChem Biosciences
      • Leicester University
      • LGC
      • LifeArc
      • McKesson
      • MD Anderson Cancer Center
      • Medicines Patent Pool Foundation
      • Medimetriks
      • MedImmune
      • Medivir
      • Melinta Therapeutics
      • MerLion
      • Merus Labs International
      • Microbiotix
      • MicuRx Pharmaceuticals
      • MSD
      • Mylan Pharmaceuticals
      • Nabriva Therapeutics
      • NAEJA Pharmaceutical
      • Nanologica
      • NanoMR
      • National Eye Institute
      • National Heart, Lung and Blood Institute
      • National Institutes of Health
      • National Institute of Allergy and Infectious Diseases
      • National Institute of Standards and Technology
      • National Science Foundation
      • Nosopharm
      • Novalar Pharmaceuticals
      • NovaMedica
      • Novartis
      • Novasep
      • OBI Pharma
      • Ohio Clinical Trials Collaborative
      • Olon
      • Onset Dermatologics
      • Oppilotech
      • Optimer Pharmaceuticals
      • Oragenics
      • PacificGMP
      • Paratek Pharmaceuticals
      • Patheon
      • Pennsylvania State University
      • Pergamum
      • Pernix Therapeutics
      • Pfizer
      • PharmaSwiss
      • Phenomenex
      • Pherecydes Pharma
      • Phico Therapeutics
      • Phosphagenics
      • Phylogica
      • Pieces Technologies
      • Polypeptide Laboratory
      • Polyphor
      • Pragma Pharmaceuticals
      • Prev AbR
      • Primetime Life Sciences
      • Procarta Biosystems
      • Proteo Biotech
      • Quintiles
      • Quotient Bioresearch
      • R-Pharm
      • Rafarma Pharmaceuticals
      • Raptor Pharmaceutical
      • RaQualia Pharma
      • Rempex Pharmaceuticals
      • Research Council of Norway
      • RMX Biopharma
      • Roche
      • RRD International
      • Rutgers University
      • Salix Pharmaceuticals
      • Sandoz
      • Sanofi
      • Savara Pharma
      • Sciex
      • Scripps Research Institute
      • Selcia
      • Senju Pharmaceutical
      • Sequella
      • Shanghai Knowshine
      • Shanghai MengKe Pharmaceuticals
      • Shanghai Zhangjiang Biomedical Industry Venture Capital
      • Shanglian Biochemical Medicine
      • Shenzhen China Resources Gosun Pharmaceutical
      • Shionogi
      • Shire Pharmaceuticals
      • SIFI (Societa Industria Farmaceutica Italiana)
      • Sigma-Tau
      • SinSa Labs
      • SINTEF
      • SI Pharmaceuticals
      • Specialised Therapeutics
      • Spero Therapeutics
      • Statens Serum Institute
      • Stratos Group
      • Strides Arcolab
      • Strox Biopharmaceuticals
      • Summit Therapeutics
      • Swedish Orphan Biovitrum
      • Swedish University of Agricultural Sciences
      • Synthetic Biologics
      • TaiGen Biotechnology
      • TB Alliance
      • TCG Life Sciences
      • Technology Strategy Board (UK)
      • Tetraphase Pharmaceuticals
      • Teva Pharmaceutical Industries
      • Texas A&M University
      • Theravance
      • The Medicines Company
      • The Regents of the University of California
      • Tongli Pharmaceuticals
      • Toyama Chemical
      • TranScrip
      • TransPerfect Trial Interactive
      • Tripex Pharmaceuticals
      • Trius Therapeutics
      • University of California, San Diego (UCSD) School of Medicine
      • University of California Berkeley
      • University of California San Francisco
      • University of Florida Research Foundation
      • University of North Carolina
      • University of Pennsylvania
      • University of Sherbrooke
      • University of Technology Sydney
      • University of Washington
      • US Army Medical Research Institute of Infectious Diseases
      • UT Southwestern Medical Center
      • Valeant Pharmaceuticals
      • Vansen Pharma
      • Venus Remedies
      • Vernalis
      • Vertex Pharmaceuticals
      • Viropharma
      • Walter Reed Army Institute of Research
      • Warner Chilcott
      • Warp Drive Bio
      • Wellcome Trust
      • Wockhardt
      • X-Biotix Therapeutics
      • X-chem
      • XBiotech
      • Xellia Pharmaceuticals
      • Yissum Research Development
      • ZAI Laboratory
      • Zhejiang Medicine
    • Antibiotics deals by stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Regulatory
      • Marketed
      • Formulation
    • Antibiotics deals by deal type
      • Asset purchase
      • Bigpharma outlicensing
      • Co-development
      • Collaborative R&D
      • Co-market
      • Co-promotion
      • CRADA
      • Development
      • Distribution
      • Equity purchase
      • Evaluation
      • Grant
      • Joint venture
      • Licensing
      • Manufacturing
      • Manufacturing - OEM
      • Marketing
      • Option
      • Research
      • Settlement
      • Spin out
      • Sub-license
      • Supply
      • Termination
    • Antibiotics deals by therapy area
      • Cardiovascular
      • Congestive heart failure
      • Hypercholesterolemia
      • Hypertension
      • Epilepsy
      • Pain
      • Dental
      • Dental caries
      • Mouth ulcer
      • Oral health
      • Dermatology
      • Acne
      • Diabetic foot ulcer
      • Impetigo
      • Wound healing
      • Gastrointestinal
      • Gastritis
      • Inflammatory bowel disease
      • Crohn's disease
      • Peptic ulcer
      • Duodenal ulcer
      • Bowel movement
      • Diarrhea
      • Genetic disorders
      • Cystic Fibrosis (CF)
      • Genitourinary
      • Urinary tract infection (UTI)
      • Symptoms
      • Infertility
      • Vaginitis
      • Hospital care
      • Surgery
      • Orthopedics
      • Immunology
      • Allergy
      • Inflammation
      • Infectives
      • Bacterial
      • Anthrax
      • Clostridium difficile
      • Escherichia Coli (E-coli)
      • Group A Streptococcus
      • Group B Streptococcus
      • Helicobacter Pylori
      • Methicillin-resistant Staphylococcus aureus (MRSA)
      • Pseudomonas aeruginosa
      • Sepsis
      • Tuberculosis (TB)
      • Fungal
      • Parasitic
      • Tropical
      • Malaria
      • Herpes simplex
      • Influenza
      • Metabolic
      • Liver disease
      • Hip
      • Knee
      • Oncology
      • Breast cancer
      • Ophthalmics
      • Age-related macular degeneration
      • Dry eye
      • Diabetic retinopathy
      • Orphan disease
      • Pediatrics
      • Public Health
      • Respiratory
      • Bronchitis
      • Pneumonia
      • Sinusitis
      • Bacterial vaginosis
      • Gonorrhea
    • Deal type definitions
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report